Hoechst Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Sanofi

Sanofi-aventis

Gerhard Seibert

Susanne Grabley

Joachim Wink

Axel Zeeck

Walter Durckheimer

Hartmut Voelskow

Carlo Giani

Wolfgang Raether

Werner Aretz

Peter Hammann

Dirk Bottger

Peter Welzel

Klaus Hutter

Kurt Hobert

Alois Tumulka

Dieter Isert

Friedhelm Adam

Hermann Uhr

Burkhard Sachse

Klaus Kuhlein

Michael Kurz

Rudolf Lattrell

Astrid Markus

Luigi Toti

Gerd Fischer

Sabine Breiding-Mack

Susanne Dobreff

Volker Teetz

Wilfried Schwab

Laszlo Vertesy

Jozsef Aszodi

Hans-Wolfram Fehlhaber

Gerhard Kretzschmar

Jurgen Blumbach

Richard H Rupp

Herbert Kogler

Dieter Duwel

Irvin Winkler

Elmar Schrinner

Hans Guehring

Bimal N Ganguli

Johannes Meiwes

Cordula Hopmann

Michael Limbert

Mark Broenstrup

Ludwig Kuhlmann

Udo Hedtmann

Sugata Chatterjee

Axel Steinstrasser

Reiner Kirrstetter

Dominique Le Beller

Karl-Heinz Bremer

Burkhard Mencke

Karl-Heinz Scheunemann

Roderich Süssmuth

Holger Hoffmann

Norbert Klesel

Ravi Gajanan Bhat

Nirogi Venkata Satya Ramakrishna

G&uuml;nther Riess

George M Sheldrick

Erich Oberhausen

Hans-Joachim Schroth

Kathrin Meindl

Rajendra Prakash Tanpure

Uttara Vinayak Oak

Shantilal Dayaram Naker

Erra Koteswara Satya Vijayakumar

Eyyammadichiyil Sankaranarayanan Sreekumar

Deepak K Chatterjee

Rajendra K Jani

Sukumar Chatterjee

László Vértesy

Burghard Mencke

L&aacute;szl&oacute; Vertesy

George Sheldrick

The disclosure relates to a compound of the formula (I) wherein

[object Object]

The invention relates to the use of a compound of the formula (I) for the treatment of bacterial infections caused by mycobacteria, nocardia or corynebacteria, wherein E is phosphorus; X, Xand Xare oxygen; and Rand Rare as defined in the specification.

Use of cyclipostin derivatives for the treatment of mycobacterial infectious diseases

The present invention relates to a compound named Vancoresmycin which is obtainable by cultivation of the microorganism HIL-006734 (DSM 12216), and to its pharmaceutically acceptable salts. The present invention further relates to a process for the production of Vancoresmycin, to the microorganism HIL-006734 (DSM 12216), to the use of Vancoresmycin and its pharmaceutically acceptable salts as pharmaceuticals, and in particular to their use as antibiotics, and to pharmaceutical compositions comprising Vancoresmycin or a pharmaceutically acceptable salt thereof.

Vancoresmycin, a process for its production and its use as a pharmaceutical

Moenomycin and its derivatives are suitable for the production of pharmaceuticals for the treatment of gastric ulcers and for the control of

Moenomycin and its derivatives for the production of pharmaceuticals, and pharmaceuticals containing moenomycin or its derivatives

The invention relates to lipopeptides with very homologous amino-acid sequences but different fatty acid residues (lipid portion) which are synthesized by Actinoplanes sp. during fermentation and are released into the culture medium, to a process for isolating the lipopeptides from the culture medium and purifying them, to the use of the lipopeptides as pharmacologically active substances, in particular against Gram-positive bacteria, and to Actinoplanes sp. DSM 7358 for producing the abovementioned lipopeptides.

Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof

The present invention relates to bismuth salts of antibiotics of the moenomycin group, processes for their preparation, their use and pharmaceuticals comprising such salts. The salts according to the invention contain antibiotics of the moenomycin group which are so-called phosphoglycolipid antibiotics and which are present individually or as a mixture, or derivatives thereof, and bismuth in defined stoichiometric ratios. They are outstandingly suitable, in particular, for controlling Helicobacter pylori and, thus, for example, for the therapy and prophylaxis of gastric disorders.

Bismuth salts of antibiotics of the moenomycin group, processes for

Penicillium cultures capable of producing 10-member ring lactones. It is possible with the aid of Penicillium strains to prepare new 10-membered ring lactones having a pharmacological action.

Penicillium cultures capable of producing 10-membered ring lactones

A new Bacillus species and the appropriate enzymes obtained therefrom can be used to break down phosphoglycolipid antibiotics. The breakdown products of moenomycins display antibiotic activity or can be used as building blocks for the synthetic preparation of transglycosylase inhibitors.

Bacillus strain for breaking down moenomycins

A new microorganism for breaking down moenomycins, a process for the breakdown, and the use of the breakdown products are disclosed. A new Bacillus species and the appropriate enzymes obtained therefrom can be used to break down phosphoglycolipid antibiotics. The breakdown products of moenomycins display antibiotic activity or can be used as building blocks for the synthetic preparation of transglycosylase inhibitors.

Microorganism for breaking down moenomycins, a process for the

Cephalosporin derivatives of the general formula ##STR1## pharmaceutical preparations which are active against bacterial infections and contain such cephem derivatives, processes for the preparation of the cephem derivatives and the pharmaceutical preparations and the use of the cephem derivatives for combating bacterial infections.

Cephalosporin derivatives

A new Bacillus species and the appropriate enzymes obtained therefrom can be used to break down phosphoglycolipid antibiotics. The breakdown products of moenomycins display antibiotic activity or can be used as building blocks for the synthetic preparation of transglycosylas inhibitors.

Enzymes for breaking down moenomycins

It is possible with the aid of various Streptomycetes species to prepare new compounds having a furan or lactone structure. These compounds have a pharmacological, especially antibiotic, action.

Process for the production of furans and lactones from streptomyces

2-alkenyloxy-3-(phosphono)oxypropanoic acids derived from the cleavage

Streptomyces parvullus, DSM 3816, produces on aerobic fermentation new antibiotics which are distinguished by antimicrobial activity even after derivatization.

Streptomyces parvullus DSM 3816

New furans and lactones from streptomycetes, a process for the preparation thereof, and the use thereof. It is possible with the aid of various streptomycetes species to prepared new compounds having a furan or lactone structure. These compounds have a pharmacological, especially antibiotic, action.

Furans and lactones from sterptomycetes and the use thereof

Growing community of inventors

Darmstadt, Germany

Gerhard Seibert